kamalbas
Repair Therapeutics shares (Nasdaq:RPTX) fell 38% in after-market trading on Thursday after the company reported phase 1 data on lunresertib and camonsertib as a combination treatment for endometrial and ovarian cancer.
The data showed that the combination achieved a
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1278425165/image_1278425165.jpg?io=getty-c-w750
Source link